Late-Session Earnings Bonanza: Ford, Chipotle, Snap & More
https://www.zacks.com/stock/news/2222125/late-session-earnings-bonanza-ford-chipotle-snap-more?cid=CS-ZC-FT-ahead_of_wall_street-2222125
Feb 06, 2024 - Markets bounced back this Tuesday from a Monday sell-off, though not all the way back to Friday highs.
0
Earnings Data Deluge
https://www.zacks.com/stock/news/2221920/earnings-data-deluge?cid=CS-ZC-FT-economic_highlights-2221920
Feb 06, 2024 - Earnings Data Deluge.
0
Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More
https://www.zacks.com/stock/news/2221113/drug-biotech-stocks-q4-earnings-due-on-feb-6-amgn-lly-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2221113
Feb 05, 2024 - Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
0
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More
https://www.zacks.com/stock/news/2215085/biotech-stock-roundup-gild-down-on-study-results-inbx-gains-on-sanofi-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2215085
Jan 24, 2024 - Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.
0
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal
https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214367
Jan 23, 2024 - Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
0
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2211770/gilead-sciences-gild-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2211770
Jan 17, 2024 - In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.
0
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
https://www.zacks.com/stock/news/2206596/gilead-sciences-gild-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2206596
Jan 05, 2024 - In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.
0
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More
https://www.zacks.com/stock/news/2201158/biotech-stock-roundup-cgen-up-on-gild-deal-mrna-gains-on-study-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2201158
Dec 21, 2023 - Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
0
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
https://www.zacks.com/stock/news/2200585/gilead-gild-compugen-collaborate-for-immunotherapy-program?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200585
Dec 20, 2023 - Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
0
Pages: 12
<Page 2